???Celebrating 4 amazing years of Cogent!?? This October marks our 4th birthday, and we're grateful to our dedicated Cogentians who make every day count. Here's to many more years of growth, innovation, and success together! #CogentTurns4 #TeamCelebration
Cogent Biosciences
生物技术研究
Waltham，Massachusetts 11,648 位关注者
Precision therapeutics for genetically defined diseases. Real solutions for real challenges.
关于我们
Cogent Biosciences is a biotechnology company focused on developing novel precision therapies to treat a broad range of patients with unmet medical needs. Cogent’s lead program, bezuclastinib, is designed to selectively and potently inhibit exon 17 mutations found within the KIT receptor tyrosine kinase, including KIT D816V. KIT D816V is responsible for driving a rare and serious condition called Systemic Mastocytosis, and exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. Bezuclastinib has already exhibited promising early clinical activity and safety in a Phase 1/2 trial in patients with advanced GIST and also has the potential to fill an unmet need for patients living with Systemic Mastocytosis.
- 网站
-
https://www.cogentbio.com
Cogent Biosciences的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- Waltham，Massachusetts
- 类型
- 上市公司
- 创立
- 2014
- 领域
- gastrointestinal stromal tumors (GIST)、Oncology、Systemic Mastocytosis和kinase inhibitors
地点
Cogent Biosciences员工
动态
-
Cogent Biosciences?is hiring! See Dana’s role and more on our Careers page: https://lnkd.in/gUJfSJ_v #careers?#hiring
-
-
As patient advocates, we deeply admire the strength and commitment shown by everyone involved—patients, caregivers, and investigators alike. This dedication brings hope for new treatment options for GIST patients. #ThrivingTogether #GIST #clinicaltrials Cogent Biosciences
We’re thrilled to announce some exciting updates to our bezuclastinib programs, including the completion of enrollment in our Phase 3 PEAK trial for patients living with #GIST. Read more: https://bit.ly/47jpdNi
-
-
Drs. @pankitvachhani and @bose_prithviraj will present our two encore posters today at the 2024 Society of Hematologic Oncology Annual Meeting (SOHO 2024) in Houston. Our Medical Affairs team is attending and looks forward to meeting with physicians and experts. Hope to see you there! #NonAdvSM #AdvSM
-
-
We’re thrilled to announce some exciting updates to our bezuclastinib programs, including the completion of enrollment in our Phase 3 PEAK trial for patients living with #GIST. Read more: https://bit.ly/47jpdNi
-
-
Cogent is a proud participant of the BStrong Ride! This year, 763 cyclists united to support cancer patients and their families. Raising over $371,000, adding to the $4M+ total since 2011. Together, we’re making a real impact! ??♂???♂???♂? #BStrongRide #CogentSupports #MakingImpact
-
-
It’s not just about the work we do, but the bonds we build. Here’s to celebrating success, teamwork, and sunny days together. Hope everyone’s summer is as incredible as ours! ?????? #TeamSpirit #SummerOuting #StrongerTogether
-
-
Today we reported our 2Q 2024 financials. Read the release here https://bit.ly/4fClbmX.
-
-
We are incredibly grateful to Cogent Biosciences for their amazing support during Life Fest San Jose. Thanks to?their Patient Advocacy Team,?Dena Westphalen, PharmD, and a quirky Plinko game, our community had a blast &?helped raise an incredible $5,000 gift to support #GISTresearch & the creation of #GISTeducation materials. Cogent also enlisted poet Elizabeth Burch-Hudson from ARS Poetica (arspoetica.us)?to work with patients & caregivers providing a truly personal, inspired experience creating GIST Verses. Thank you, Cogent, for your continued partnership &?commitment to our mission! Together, we thrive!??? #LifeFest2024 #ThrivingTogether #gastrointestinalstromaltumor
-
-
Today we celebrate?#NationalInternDay?and we can confirm how impressed we are by the accomplishments of?our?2024 interns
-